Pan‑cancer Analysis of LAP2α as a Potential Prognostic and Immunological Biomarker for Multiple Cancer Types Including Glioma

Abstract

Abstract LAP2α, a variant of the lamin-associated polypeptide 2 (LAP2) family, is crucial for in the process of nuclear structure organization and maintaining genomic stability. This research was aimed to investigate the involvement of LAP2α in cancer development, especially in glioma. Based on public datasets, we found LAP2α was upregulated in most cancers, and the survival analysis indicated a distinct correlation between elevated LAP2α expression and unfavorable prognosis among glioma patients with elevated levels of macrophage and neutrophil. LAP2α level evidently associated with the immune checkpoint therapy related genes in cancers. Specifically, we made the tissue microarray covered 80 glioma patients with prognostic analysis, and verified that reducing LAP2α hindered the growth and movement capacity of the glioma cells. Our data suggests that LAP2α may be an important tool for indication of immunotherapy and medical prognosis in pan-cancer, and is expected to have a critical role in the oncogenesis of glioma.